CN1282577A - Application of dimethyl sulfoxide in improving sensitivity of antibiotics to bacteria - Google Patents
Application of dimethyl sulfoxide in improving sensitivity of antibiotics to bacteria Download PDFInfo
- Publication number
- CN1282577A CN1282577A CN 00113470 CN00113470A CN1282577A CN 1282577 A CN1282577 A CN 1282577A CN 00113470 CN00113470 CN 00113470 CN 00113470 A CN00113470 A CN 00113470A CN 1282577 A CN1282577 A CN 1282577A
- Authority
- CN
- China
- Prior art keywords
- dimethyl sulfoxide
- bacteria
- application
- dmso
- sensitivity
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
An application of dimethyl sulfoxide in 7 areas including to increase sensitivity of various antibiotics to bacteria is disclosed. Its advantages are stable quality, convenient application and high curative effect. A new usage of natural compound dimethyl sulfoxide is created.
Description
The present invention relates to a kind of native compound among the human lives in pharmaceutically new application.
Dimethyl sulfoxide is a kind of natural chemical compound, although at present human it is researched and developed aspect wrapping with straw the doctor, and found that it has the effect of diuresis, antiinflammatory, and but its a lot of purposes is not found, dimethyl sulfoxide does not become a kind of clinical medicine yet till today.
The object of the present invention is to provide a kind of native compound improving all kinds of antibiotic to the sensitivity of antibacterial and eliminate the new purposes pharmaceutically of the aspects such as Drug resistance of antibacterial.
Dimethyl sulfoxide (DMSO) character: DMSO is a colourless transparent liquid, several odorlesses, and mildly bitter flavor, hygroscopicity is very strong, proportion 1.1014,189 ℃ of boiling points.Can be miscible with water, ethanol, acetone.Under anhydrous condition, also can be miscible with ether, chloroform, benzene.Unsaturated hydrocarbons is had very high solvability, and many inorganic salts also can dissolve.2.16% aqueous solution is an isosmotic solution.
Effect and mechanism: pharmacological experiment study proves that DMSO is a low toxicity, and also be of short duration action time.Give an intravenous injection DMSO of mice stock solution, its LD50 dose is 3.94 ± 0.87 gram/kg body weight, its safe dose 2.64 gram/kg body weight.Give the frozen bone marrow of lean type of mice and Canis familiaris L. infusion 10%DMSO,, do not see other untoward reaction except that the gas of breathing out has the abnormal flavour.In the human body autologous bone marrow transplantation, generally gather bone marrow (adult) 450-1200 milliliter, press the frozen back of 10%DMSO infusion, then the DMSO consumption is the 45-120 milliliter, and does not see the untoward reaction report clinically.From the 53 routine tumor cases that I did, DMSO consumption 0.2-0.5 milliliter/kilogram logotype 1-7 days, is not seen untoward reaction.
Clinical indication: 1. infectious disease: DMSO and all types of antibiotic compatibility can improve antibiotic curative effect and to a certain degree eliminate drug-resistance of bacteria.2. to the effective all types of tumors of chemotherapeutics: DMSO and antitumor drug share the curative effect that can improve chemotherapeutics and can eliminate the drug resistance of tumor cell to a certain extent, and prolonged patient's life cycle greatly.To the pernicious ascites pleural fluid patient of intractable, intracavitary administration has significant curative effect especially.3. toxemia: DMSO can alleviate and destroy the infringement of bacteriotoxin to human body to a certain extent.4. cerebral edema: DMSO can alleviate cerebral edema.5. acute myocardial infarction DMSO can protect because of the soon dead myocardial cell of ischemia.6. type: DMSO can increase the sensitivity of body to insulin.7. dimethyl sulfoxide has the effect of bacteria growing inhibiting.
Dosage and usage: 1. intravenous injection: DMSO 10-25 milliliter adds normal saline or Glucose Liquid, is made into to be not more than 20% final concentration liquid intravenous drip.2. injection in the splanchnocoel: after exhausting hydrops, DMSO 10-20 milliliter is added 20 milliliters of injections of normal saline.
Medicine preparation: select the degerming of medical pure DMSO sucking filtration for use, 10 milliliters/of packing.
Dimethyl sulfoxide is the molten coal of polarity, and solubility property is good, and very strong permeability is arranged.It is a kind of cell freezing protective agent; the freezing that is widely used in various internal organs organs is preserved; its principle is because its energy quick penetration cell membrane; open the inside and outside crystalloid osmotic pressure of its cell of cell membrane balance, thereby reduce in its freezing and course of defrosting owing to cell permeability swelling causes cell rupture death.We utilize dimethyl sulfoxide one can open cell membrane two can inside and outside these two characteristics of crystalloid osmotic pressure of statocyte reach above several aspects clinical therapeutic efficacy.The new purposes of dimethyl sulfoxide brings great wealth and Gospel for the pharmaceutical sector and the extensive patients of China.
Claims (1)
1. dimethyl sulfoxide improves all kinds of antibiotic at a and the sensitivity of antibacterial and Drug resistance, b and the antitumor drug of eliminating antibacterial are share the curative effect that improves chemotherapeutics and Drug resistance, the c that eliminates tumor cell alleviates and destroys bacteriotoxin and infringement, the d diuresis of human body alleviated cerebral edema, e myocardial infarction patient protection is about to myocardial cell, f increase diabetics because of ischemia death soon to the purposes of aspects such as the sensitivity of insulin, g bacteria growing inhibiting.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00113470 CN1282577A (en) | 2000-05-31 | 2000-05-31 | Application of dimethyl sulfoxide in improving sensitivity of antibiotics to bacteria |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 00113470 CN1282577A (en) | 2000-05-31 | 2000-05-31 | Application of dimethyl sulfoxide in improving sensitivity of antibiotics to bacteria |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1282577A true CN1282577A (en) | 2001-02-07 |
Family
ID=4583250
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 00113470 Pending CN1282577A (en) | 2000-05-31 | 2000-05-31 | Application of dimethyl sulfoxide in improving sensitivity of antibiotics to bacteria |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1282577A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102724973A (en) * | 2009-10-30 | 2012-10-10 | 生物基因创新有限责任公司 | Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms |
| US8546373B2 (en) | 2009-10-30 | 2013-10-01 | Biogenic Innovations, Llc | Methods of sensitizing drug resistant microorganisms using methylsulfonylmethane (MSM) |
| WO2020015732A1 (en) * | 2018-07-20 | 2020-01-23 | 北京蔚蓝之源医药科技有限公司 | Uses of sulfoxide compound for preventing nervous system diseases |
-
2000
- 2000-05-31 CN CN 00113470 patent/CN1282577A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102724973A (en) * | 2009-10-30 | 2012-10-10 | 生物基因创新有限责任公司 | Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms |
| US8546373B2 (en) | 2009-10-30 | 2013-10-01 | Biogenic Innovations, Llc | Methods of sensitizing drug resistant microorganisms using methylsulfonylmethane (MSM) |
| CN102724973B (en) * | 2009-10-30 | 2014-08-27 | 生物基因创新有限责任公司 | Methylsulfonylmethane (MSM) for treatment of drug resistant microorganisms |
| WO2020015732A1 (en) * | 2018-07-20 | 2020-01-23 | 北京蔚蓝之源医药科技有限公司 | Uses of sulfoxide compound for preventing nervous system diseases |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8530507B2 (en) | Use of levo-ornidazole in the preparation of anti-anaerobic bacteria infection drugs | |
| AU3514799A (en) | Novel pharmaceutical composition for use in emergency treatment and preparation method thereof | |
| Malpas et al. | Rubidomycin in acute leukaemia in adults | |
| CA2529598C (en) | Stable freeze-dried pharmaceutical formulation of tetrodotoxin | |
| Mordenti et al. | Combination antibiotic therapy: comparison of constant infusion and intermittent bolus dosing in an experimental animal model | |
| CN102100666B (en) | New moxifloxacin hydrochloride injection | |
| KR20090095668A (en) | A forsythoside injection and preparation thereof | |
| JP2006501199A (en) | Formulation and administration method of cephalotaxin containing homoharringtonine | |
| Neidhart et al. | Phase I trial of homoharringtonine administered by prolonged continuous infusion | |
| CN100493514C (en) | Composite medicine of creatine phosphate sodium and magnesium salt | |
| CN1282577A (en) | Application of dimethyl sulfoxide in improving sensitivity of antibiotics to bacteria | |
| KR100312622B1 (en) | Stabilized anticancer composition mainly composed of herbal medicine and its manufacturing method | |
| US9125877B2 (en) | Use of kauranes compounds in the manufacture of medicament | |
| CN101467967B (en) | Double-element solution type preparation for intravenous injection and intracerebral injection | |
| EP1121930B1 (en) | Drug preparation "histochrome" for treating acute myocardial infarction and ischaemic heart diseases | |
| CN101423516A (en) | Preparation of pidotimod sodium and medicinal use thereof | |
| CN101313914B (en) | Uses and preparations of common camptotheca fruit glycosides of common camptotheca fruit extract | |
| CN101966196A (en) | Formula of catalpol-puerarin injection and powder and preparation method | |
| CN100408047C (en) | Medicinal composition of fructose diphosphate sodium and magnesium salt | |
| CN102008461B (en) | A kind of ibuprofen drug composite for injection | |
| CN101209343A (en) | Preparations for treating mastitis of cow and preparation thereof | |
| CN101559037B (en) | Binary solution type preparation for intravenous injection and intracerebral injection | |
| CN1325051C (en) | Compound medicine of ozagrel and its salt and troxerutin | |
| CN101768156A (en) | Pidotimod arginine salt and preparation thereof | |
| CN101554368A (en) | Tetrodotoxin composition formulation stable at room temperature and used for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| C10 | Entry into substantive examination | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |